← Back to Startups

Rgenta Therapeutics, Inc.

On its website, the company describes its work as “Rgenta analyzes vast genomic data with proprietary methods to pinpoint interactions of the splicing machinery and RNA best suited for small molecule binding, designing and…”.

Industry
Other Technology
Tracked VC backers
0
View in My Fund →
Limited coverage
Tracking coverage and points

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Limited coverage
Verified filings recorded. Existing baseline history earns no points.SEC source checked:
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Publicly documented VC backing

These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.

No tracked VC backing is recorded.

Dated public activity

· Form D filing

Reported sold as filed: $41,852,307 · Offering amount as filed: $130,107,279

SEC source checked 5 Nov 2026. This is the issuer’s historical filing, not a current valuation.

View original evidence ↗